Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Last trade$7.74
Day change-$0.03 (-0.39%)
Day range$7.54 – $7.87
Volume86,190
Market cap$489M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$488.76M
Price / earnings
—
Price / book
8.18×
Price / sales
10.64×
EV / sales
10.78×
EV / EBITDA
-57.18×
Profitability
Earnings per share
-$0.25
Return on assets
-16.87%
Return on equity
-26.72%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.22×
Current ratio
3.56×
Quick ratio
2.72×
Cash ratio
0.74×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.38M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TKNO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$12.7M
$12.19M
$11.08M
$9.98M
$10.45M
$10.29M
$10.28M
$9.27M
Cost of revenue
$7.88M
$7.3M
$7.29M
$6.74M
$7.25M
$6.3M
$6.79M
$7.14M
Gross profit
$4.83M
$4.89M
$3.78M
$3.24M
$3.21M
$3.98M
$3.49M
$2.13M
Selling, general and administrative
$7.16M
$6.93M
$7.19M
$7.04M
$6.39M
$6.5M
$7.13M
$6.88M
Research and development
$581K
$554K
$609K
$522K
$542K
$581K
$552K
$594K
Total operating expenses
$8.03M
$7.78M
$8.08M
$7.85M
$7.22M
$7.37M
$7.97M
$7.76M
Operating income
-$3.21M
-$2.89M
-$4.3M
-$4.61M
-$4.02M
-$3.39M
-$4.48M
-$5.63M
Interest expense
-$259K
-$252K
$0
-$211K
-$190K
-$165K
$0
-$129K
Income before taxes
-$3.46M
-$3.14M
-$4.51M
-$4.82M
-$4.21M
-$3.55M
-$4.62M
-$5.76M
Income taxes
$34K
$30K
$47K
-$62K
$79K
$19K
$22K
-$38K
Net income
-$3.49M
-$3.17M
-$4.56M
-$4.76M
-$4.29M
-$3.57M
-$4.65M
-$5.72M
Net income attributable to common shareholders
-$3.49M
-$3.17M
-$4.56M
-$4.76M
-$4.29M
-$3.57M
-$4.65M
-$5.72M
EBITDA
-$1.62M
-$1.3M
-$2.72M
-$3.03M
-$2.43M
-$1.8M
-$2.9M
-$3.98M
Basic earnings per share
-$0.06
-$0.06
-$0.08
-$0.09
-$0.08
-$0.07
-$0.09
-$0.11
Diluted earnings per share
-$0.06
-$0.06
-$0.08
-$0.09
-$0.08
-$0.07
-$0.09
-$0.11
Recent news
Company coverage with links to the original publishers.
Alpha Teknova (TKNO) shares rose 5.1% to $6.15 after announcing robust preliminary Q3 2026 financial results with revenues expected between $12.5-$12.7 million. Despite the rally, the stock remains down 34.5% over the past four weeks. The company is expected to post a quarterly loss of $0.06 per share with revenues up 12% year-over-year. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the recent jump may lack sustained momentum.
Alpha Teknova (TKNO) announced it will report third quarter 2026 financial results on November 4, 2026, followed by a webcast and conference call at 6:00 p.m. ET. The company, a producer of critical reagents for life sciences, also recently announced a $40 million public offering of common stock.
Alpha Teknova (TKNO) announced the pricing of an underwritten public offering of 8 million shares at $5.00 per share, generating $40 million in gross proceeds. The offering is expected to close on October 22, 2026. Teknova intends to use net proceeds for general corporate purposes, including potential debt repayment and strategic acquisitions.
Alpha Teknova (TKNO) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months with a 5.2% increase in consensus estimates. The upgrade positions the biopharmaceutical reagent maker in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving business fundamentals.
Teknova and Pluristyx are collaborating to produce and commercialize Pluristyx's PluriFreeze cryopreservation system, which is designed to simplify the scale-up process for companies working to bring allogeneic cell therapies to market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.